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1. Introduction 
Pluripotent stem cells have the capacity to develop into different cell lineages, and can be 
promoted into skeletal muscle lineage through the use of small molecule inducers. Retinoic 
acid (RA) signaling through the retinoic acid receptor (RAR) and retinoid X receptor (RXR), 
is important for embryonic development, and is able to enhance myogenic differentiation in 
vitro if used in combination with other small molecule inducers. Nevertheless, it only yields 
moderate results in promoting the differentiation of embryonic stem (ES) cells into skeletal 
myocytes. RXR is also known to be essential for embryonic development, but it is generally 
considered to act as a silent partner for other nuclear receptors such as RAR. We recently 
discovered that RXR selective ligand efficiently induces myogenic differentiation in mouse 
ES cells which respond poorly to RA. In addition, myogenic differentiation, enhanced by the 
RXR ligand, is mediated through a RAR independent mechanism, and recapitulates closely 
the sequential events observed in vivo. Since ES cell differentiation represents the properties 
of early developing embryo, efficiently generating skeletal myocytes with RXR selective 
ligand provides means to further scrutinize signaling pathways in skeletal myogenesis, in 
view of developing cell-based therapies for skeletal muscle-related diseases. In this chapter, 
we attempt to provide an in-depth analysis of recent research findings and the current stage 
of knowledge in the field of skeletal myogenesis. 
2. The retinoid X and retinoic acid receptors  
RXR belongs to the nuclear hormone receptor superfamily, such as steroid hormone, thyroid 
hormone, vitamin D receptors, and nuclear receptors including RAR, PPAR, LXR and PXR 
(Szanto et al., 2004). It is a very unique protein with the ability to form heterodimers with one 
third of the 48 other nuclear receptors (Mangelsdorf et al., 1995) giving it the potential to 
converge a large array of signaling pathways. The RXR can form homodimers, permissive 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 50 
heterodimers, and non-permissive heterodimers  in a ligand-dependent or -independent 
manner (Tanaka and De Luca, 2009). When RXR forms homodimers or permissive 
heterodimers (with PPAR, LXR, PXR etc.), it is amenable to RXR ligand-dependant activation 
since the activation domain of the partner receptor is placed in proximity to RXR helixes. Once 
RXR is activated by the ligand, conformational changes cause direct stabilization of the 
activation domain of its partner (Gampe, Jr. et al., 2000b). When RXR forms non-permissive 
heterodimers (with RAR, VDR, TR etc.), it is not activated by ligand, as the binding of the 
partner receptor to RXR allosterically inhibits it (Kurokawa et al., 1994; Tanaka et al., 2009). 
Furthermore, the activation domain of the partner is not located in proximity to ligand 
activated residues in the RXR interface (Bourguet et al., 2000; Gampe, Jr. et al., 2000b). 
2.1. DNA binding 
The receptor dimers of RXR and its partner, constitutively bind to specific DNA response 
elements in the promoters or enhancers of the genes they govern. DNA binding specificity is 
determined by the number of spacer nucleotides present between two direct repeats of the 
canonical binding sequence 5’-PuGGTCA (Leid et al., 1992; Umesono and Evans, 1989). The 
RXR/RAR heterodimers bind to the retinoic acid response element (RARE) with a consensus 
half site separated by 2 or 5 nucleotides (DR2 or DR5), whereas the RXR homodimers bind to 
the retinoid X response element (RXRE) separated by only one nucleotide (DR1) (Tanaka et al., 
2009) (Figure 1). Selective response element recognition is due to a short sequence (the P box) 
located at the C-terminal base of the N-terminal C1 finger of the DNA binding domain (DBD) 
which interacts with the binding motif, and also due to a weak dimerization function which 
encompasses the N-terminal base of the CII finger (D-box) of the DBD (Danielsen et al., 1989; 
Green et al., 1988; Kumar and Chambon, 1988; Luisi et al., 1991; Mader et al., 1989; Umesono et 
al., 1989). While RXR/RAR heterodimers bind more effectively to the RAREs than RXR 
homodimers, RXRs homodimers can bind RXREs with high affinity (Zhang et al., 1992). 
RAREs can overlap with RXREs, and since RXR/RAR heterodimers bind with a higher affinity 
than RXR homodimers, (Tanaka et al., 2009), this may interfere with RXR signaling. 
 
Figure 1. The Binding of RXR/RAR Heterodimer and RXR Homodimer to DNA. RXR/RAR 
heterodimers (left) and RXR homodimers (right) bind via the DNA binding domain to two direct 
repeats of the canonical binding sequence 5’-PuGGTCA separated by 2 or 5 nucleotides, or 1 nucleotide 
respectively.  
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2.2. Ligands of RXR and RAR 
While RXR and RAR constitutively bind to DNA, they require agonist binding to activate 
gene transcription. Several endogenous ligands are well characterized and many synthetic 
ligands have been developed. 
RA, the active derivative of vitamin A, can exist as two isoforms: all-trans RA and 9-cis RA. 
RAR bind and are activated by all-trans RA as well as its 9-cis isomer, while the RXR bind 
and are activated only by 9-cis RA (Ricaud et al., 2005). However, due to the considerable 
difficulty of detecting 9-cis RA endogenously in embryos or in adult tissue (Niederreither 
and Dolle, 2008), there has been debate about the in vivo role of activated RXR, and has led 
to the belief that RXR serves only to orient and position the heterodimers properly on the 
DNA (Perlmann and Jansson, 1995; Willy et al., 1995; Willy and Mangelsdorf, 1997) 
In the last two decades, a wide range of RXR selective compounds has been engineered. The 
synthetic RXR ligands can act as agonists and activate both homodimers and permissive 
heterodimers. Conversely, they can also act antagonistically of homodimers, as is the case 
for the synthetic ligand LG100754, and promote only the activation of non-permissive 
heterodimers (Lala et al., 1996). Bexarotene (LGD1069) is a synthetic RXR selective 
compound used in the treatment of cancer. It is unable to transactivate the RXR-RAR 
heterodimer (Lehmann et al., 1992) and will not activate RARs (Nau et al., 1999). 
There are conflicting interpretations of RXR participation in the activation of RXR/RAR 
heterodimers. Some studies demonstrate that allosteric inhibition of RXR in the RXR/RAR 
heterodimer only occurs when the RAR is unliganded and that this inhibition is relieved 
once RAR is liganded (Forman et al., 1995; Lala et al., 1996). Other reports indicate that both 
receptors bind their ligands independently and that their effects are additive (Kersten et al., 
1995). The discrepancy between varying reports can possibly be reconciled by the fact that 
different ligands interact with distinct side chains in the ligand binding domain and thus 
mediate differential activation of the receptor complex. The exact response is therefore 
highly dependent on the identity of the ligand and cannot simply be classified as agonistic 
versus antagonistic. Although RXR can engage in ligand binding when RAR is ligand 
occupied and/or if a suitable synthetic ligand is present (Chen et al., 1996; Kersten et al., 1996; 
Lala et al., 1996; Minucci et al., 1997; Roy et al., 1995), bexarotene is unable to transactivate the 
RXR/RAR heterodimer (Lehmann et al., 1992). In fact, bexarotene has been reported to 
reduce interactions between RXRs and RARs whereas ligand such as 9-cis increases the 
binding of RXRs to RARs (Dong and Noy, 1998).  
All-trans RA does not bind RXR (Mangelsdorf et al., 1992), and more importantly, although 
all-trans RA has the ability to isomerize to 9-cis RA, pharmacological doses of all-trans RA 
are required to generate enough 9-cis to activate the RXRs (Mic et al., 2003). Optimal 
enhancement of skeletal myogenic differentiation requires low concentrations of all-trans 
RA. Thus, all-trans RA isomerization is simply not a feasible explanation to the similar 
enhancement of myogenic differentiation by RA and bexarotene observed in P19 stem cells 
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(Le May et al., 2011). Finally, while RA metabolites, such as 4-oxo-RA, were originally 
believed to play a role in RA signaling, they have more recently been shown as 
physiologically not required (Niederreither et al., 2002; Pijnappel et al., 1993).  
2.3. The interaction of RXR and RAR with their cofactors 
In response to ligand activation, RXR and RAR bind co-activators and the respective binding 
of cofactors again depends on the identity of the ligand. Agonist binding induces large 
conformational changes within the receptor causing helix 11 and 12 (the AF-2 domain) to 
close the lid of the ligand binding pocket and generate high affinity co-activator binding 
sites. This charged surface has a high affinity for a specific amino acid motif, LXXLL, which 
mediates the binding of co-activators to nuclear receptors (Westin et al., 1998). Alternatively, 
if an antagonist or partial agonist binds, helix 12 is repositioned to an adjacent groove on the 
LBD and a charged surface that favors the co-repressor binding motif is formed (Perissi et 
al., 1999).  
Co-activators, as their name implies, have the ability to activate transcription and interact 
with the basal transcriptional machinery, bridge and direct the assembly of transcriptional 
pre-initiation complexes, and induce chromatin remodeling (Rosenfeld et al., 2006; Bastien 
and Rochette-Egly, 2004). Co-activators such as p300, CREB Binding Protein (CBP), and 
p300/CBP-Associated Factor (PCAF) can all act as histone acetyltransferases (HATs) 
(Niederreither et al., 2008; Ogryzko et al., 1996) and form large multimolecular complexes.  
Interestingly, co-activators p300 and CBP are also able to acetylate proteins other than 
histones, such as transcription factors (Gu and Roeder, 1997; Li et al. 1998; Li et al. 1999). CBP 
and p300 are heavily autoacetylated and upon recruitment to the receptors, can acetylate 
more of themselves in an intermolecular fashion (Karanam et al., 2006). In addition to this, 
they have the ability to recruit PCAF (Yang et al., 1996), a coactivator involved in 
myogenesis. p300 influences RXR activity as RXR are subjects for p300 acetylation, which 
promotes their binding to RXRE and increases their transcriptional activity as well (Zhao et 
al., 2007). Co-activators play crucial roles in gene activation, however, those recruited by 
particular RXR dimers at specific genetic loci in response to ligand have yet to be identified.  
Alternatively, in the absence of ligand, the co-repressors, such as the nuclear receptor 
corepressor (NCoR) and silencing mediator of retinoic acid and thyroid hormone receptor 
(SMRT) family, bind and recruit a mulitprotein complex containing the histone deacetylase 
HDAC3 (Guenther et al., 2000; Li et al., 2000). The recruited histone methyl-transferases and 
histone deacetylases stabilize the nucleosome structure so that the DNA is inaccessible for 
transcription (Niederreither et al., 2008).  
When RXR forms permissive heterodimers (i.e.: RXR/PPAR), neither receptor binds the co-
repressors under normal circumstances (DiRenzo et al., 1997). Ligand binding to one 
receptor recruits the co-activators and although the other receptor may be unliganded, the 
high local concentration of bound co-activators favor the docking of the second LXXLL 
motif with the co-activator binding sites of the other receptor. If ligand is present for both 
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receptors of the permissive heterodimer, they can synergistically recruit co-activators (Ahuja 
et al., 2003).  
Non-permissive heterodimers (i.e.: RXR/RAR) do bind co-repressors and this binding to 
unliganded RXR and its partner is stabilized by both receptors. Transactivation requires 
ligand binding to the RXR partner (i.e.: RAR) to convert it into the agonist conformation, 
displace co-repressors, and recruit co-activators (Zhang et al., 1999; Vivat et al., 1997). As 
with permissive heterodimers, synergistic recruitment of co-activators occurs when ligands 
are present for both receptors (Ahuja et al., 2003). 
2.4. RXR and RAR in development 
Gene mutation studies have determined that both RXR and RAR are essential for proper 
development, and delineated roles and tissue expression patterns for the different isoforms 
of the two receptors (α, β, and γ). The different RAR and RXR isotypes are encoded by 
different genes and their isoforms differ in their NH2-terminal regions which are generated 
by differential promoter usage and alternative splicing (Chiba et al., 1997). While RXR-α null 
embryos show defects in RXR/PPARγ (Peroxisome Proliferator Activated Receptor) 
signaling, the RARs appear to be the most important partners for RXRs (Ahuja et al., 2003). 
RXR/RAR non-permissive heterodimers have been extensively studied in the context of 
development. 
During development, RXR-α and β are ubiquitously expressed with the highest levels of 
RXR-α present in the liver, heart, intestines, kidney, spleen, placenta, and the epidermis 
(Ahuja et al., 2003; Pratt et al., 1998). RXR-γ is expressed in all developing skeletal and 
cardiac muscles, the anterior pituitary, and the brain. The expression of RXR isoforms is 
tissue specific and often overlaps, yet occasionally certain isoforms are uniquely 
expressed.(Mangelsdorf et al., 1992)  RXR-α is the primary isoform and supports the activity 
of all three RARs. Furthermore, RXR-α may be important in the expression of RXRγ since 
the RXR gene contains a RXRE (Barger and Kelly, 1997).  
Studies with mice lacking expression of RXR-α have found that these mice die in utero as a 
result of hypoplastic myocardium (Kastner et al., 1994; Sucov et al., 1994) and RXR-α null 
mutations exhibit growth retardation, webbed digits (Mark et al., 2006) and defects in the 
chorioallantoic placenta (Sapin et al., 1997). Loss of RXR-β and RXR-γ is not as severe since 
they can be compensated for by RXR-α (Tanaka et al., 2009), which may explain why the 
RXRγ -/- mouse mutants are viable and have no muscular defects even in compound mutant 
combinations (Dolle, 2009). 
Similarly, animals lacking RAR-α or RAR-γ result in postpartum lethality (Lohnes et al., 
1993). In RAR knock-out studies where two RARs are deleted, the mutants display a 
spectrum of defects that resemble vitamin A deficiency syndrome (Lohnes et al., 1993; 
Lufkin et al., 1993) and the function of the residual RAR is highly dependent on RXR-α 
(Ahuja et al., 2003). 
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Even in normal development, the RARs are highly dependent on the RXRs. Homodimer 
formation of RARs is energetically unfavored, because of the limited contact between the 
interfaces. Pairing with RXR creates an extended area of intermolecular contact that 
stabilizes the heterodimer formation. This substantially larger surface area and consequent 
stability, results in the preferential formation of RXR/RAR heterodimers (Bourguet et al., 
2000; Gampe, Jr. et al., 2000a).  
3. Skeletal myogenesis 
Skeletal muscle forms in the embryo from paraxial mesoderm, which segments into somites 
on either side of the neural tube and notochord (Christ and Ordahl, 1995). Extracellular 
signals from surrounding tissues play a significant role in muscle development. These 
signals include members of the Wnt family, specifically Wnt1 and Wnt7a secreted from the 
neural tube and surface ectoderm (Cossu and Borello, 1999), Sonic Hedge Hog (Shh) 
secreted by notochord and floor plate cells and which acts in conjunction with Wnt1 (Cossu 
et al., 1999), bone morphogenetic protein4 (BMP4) secreted by the lateral plate mesoderm 
cells (Borycki et al., 1999; Dietrich et al., 1998; Munsterberg et al., 1995; Pourquie et al., 1996; 
Tajbakhsh et al., 1998), and RA which is under tight regulatory control for its synthesis, 
degradation, and transport (Rohwedel et al., 1999). These act on downstream targets such as 
HOX genes, which controls specification of the body axis (Rohwedel et al., 1999), Brachyury 
T, a protein required for posterior mesoderm and notochord differentiation (Skerjanc, 1999), 
and the myogenic regulatory factors (MRFs) including Myf5, MyoD, myogenin, and Mrf4 
which are required for the commitment and maturation of skeletal muscle (Cossu et al., 1999; 
Rohwedel et al., 1999; Skerjanc, 1999). 
3.1. Myogenic regulatory factors and their cofactors  
The formation of myoblasts from myogenic progenitors and their successive cell cycle arrest 
and differentiation into mature skeletal muscle involves two key families of transcription 
factors. The MyoD family of basic Helix-Loop-Helix (bHLH) proteins which includes the 
four master transcriptional regulators (also referred to as MRFs): Myf5, MyoD, myogenin, 
and Mrf4 (Arnold and Braun, 2000; Braun et al., 1989; Braun et al., 1990; Davis et al., 1987; 
Edmondson and Olson, 1990; Froeschle et al., 1998) and the myocyte enhancer factor 2 
(MEF2) family of MADS-box transcription factors which includes MEF2A, -B, -C, and –D 
(Naya and Olson, 1999).  
Myf5 and MyoD are involved in skeletal muscle specification and commitment and have the 
capacity of remodeling chromatin and opening gene loci that participate in further muscle 
differentiation (Bergstrom and Tapscott, 2001), whereas terminal differentiation is governed 
by myogenin and MRF4. Each MRF is sufficient to dominantly induce myogenesis when 
introduced into a variety of non-muscle cells (Olson, 1990; Weintraub, 1993), and ectopic 
expression of MyoD can inhibit cell cycle before the S phase independently of its DNA 
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binding and the induction of myogenic differentiation (Crescenzi et al., 1990; Sorrentino et 
al., 1990).  
Members of the MEF2 family alone are not sufficient to induce myogenesis, however the 
ability of the MRFs to convert cells is reliant on the function of the MEF2 family. MEF2 
proteins bind as homodimers and heterodimers to the consensus sequence YTA(A/T)4TAR 
found in the promoter region of nearly every known muscle-specific gene (Black and Olson, 
1998), and together with the myogenic bHLH proteins, synergistically activate the 
transcription of myogenic genes. Unlike the MRFs, MEF2 genes are also expressed outside 
the skeletal muscle lineage in tissues such as cardiac and smooth muscle (Black et al., 1998; 
Edmondson et al., 1994; Leifer et al., 1993; Lyons et al., 1995).  
 
Figure 2. Involvement of Myogenic Regulatory Factors in Myogenesis. Myf5 and MyoD are involved 
in specification and commitment of muscle progenitors into skeletal muscle lineage. Mrf4 also plays a 
role as a determination gene in addition to directing terminal differentiation along with myogenin.  
The bHLH domain of the MRFs is responsible for DNA binding and for dimerization with 
the ubiquitously expressed bHLH E protein (Hu et al., 1992; Murre et al., 1989; Parker et al., 
2006). The resulting myogenic bHLH-E heterodimers bind to DNA at the consensus 
sequences known as an E-box (CANNTG), specific DNA motifs present at muscle gene 
enhancers and/or promoters, where they regulate gene expression (Sartorelli and Caretti, 
2005). These genes include cytoskeletal, sarcomeric, metabolic, and cell signaling proteins 
(Angus et al., 2001; Gramolini and Jasmin, 1999; Kraner et al., 1999; Li and Capetanaki, 1993; 
Lin et al., 1991; Marsh et al., 1998; Shield et al., 1996; Simon and Burden, 1993; Wheeler et al., 
1999). A requirement for the MyoD family of transcription factors in this combinatorial 
complex is demonstrated by the fact that the E protein homodimers bind to the same DNA 
sequences as the MyoD-E protein heterodimers, yet only the MyoD-E protein complex can 
cooperate with MEF2 factors (Naya et al., 1999). Furthermore, the MRFs and MEF2 factors 
activate and repress each others transcription in a complex network (Arnold and Winter, 
1998; Bergstrom et al., 2002; Cserjesi and Olson, 1991; Olson and Klein, 1994; Wong et al., 
1994). For example, expression of myogenin requires MEF2, while myogenin activates the 
expression of MEF2 independently of other skeletal gene products (Cserjesi et al., 1991;  
Ridgeway et al., 2000). Similarly, MRFs can positively regulate their own transcription and 
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transcription of each other, creating positive auto- and cross-regulatory loops (Braun et al., 
1989; Thayer et al., 1989) 
3.2. Roles of meox and pax in the specification of myogenic progenitors  
Signals from surrounding tissues activate the premyogenic program, and result in the 
expression of transcription factors such as Pax3, and Meox1/2 that specify cells into the 
skeletal muscle lineage and mediate the induction of the MRFs (McDermott et al., 2005; 
Petropoulos and Skerjanc, 2002; Petropoulos et al., 2004; Ridgeway and Skerjanc, 2001; 
Williams and Ordahl, 1994).  
Pax3, a transcription factor with homeo and paired domain motifs, is thought to be activated 
by Wnt6a (Fan et al., 1997) and is responsible for both delamination and migration of muscle 
progenitors to the limb bud (Tajbakhsh et al., 1997). Pax3 is initially expressed throughout 
the somite before becoming restricted to the dermomyotome and subsequently the 
migratory muscle progenitor cells (Goulding et al., 1994; Williams et al., 1994). The 
importance of Pax3 in the delamination and migration of muscle progenitor cells is 
highlighted by the fact that mice which are Pax3 null have severe muscle loss (Alvares et al., 
2003; Bladt et al., 1995; Dietrich et al., 1999; Epstein et al., 1996; Grifone et al., 2005).  
Pax3 directly regulates the expression of Myf5 through the limb bud enhancer of Myf5 gene 
(Bajard et al., 2006) and acts with Myf5, upstream of MyoD which cannot be properly 
expressed in the Pax3/Myf5 double knockout (Tajbakhsh et al., 1997). It is when the migrating 
cells reach the limb bud that they begin to express Myf5 and MyoD, and it is both before and 
after activation of these genes that the cells undergo extensive proliferation (Buckingham et al., 
2003; Tajbakhsh and Buckingham, 1994). Pax3, along with additional factors such as Myf5, c-
met, Msx1 and the fibroblast growth factor (FGF) family of receptors promote myoblast 
proliferation. Proliferation is arrested by inhibitory signals which promote differentiation by 
inducing cell cycle arrest proteins such as MyoD (Alric et al., 1998). 
Meox1 and Meox2 are closely related homeobox genes with mesoderm and mesenchyme 
specific expression during mouse development (Candia et al., 1992). Meox1 is expressed in 
the dermomyotome whereas after delamination and migration to the limb bud, Meox2 is 
predominantly expressed (Candia et al., 1992; Candia and Wright, 1996). In Meox2 deficient 
limb buds, Pax3 and Myf5 are downregulated and mice homozygous for a null mutation in 
Meox2 have defects in limb muscle differentiation resulting in an overall reduction in 
muscle mass and absence of specific muscles (Mankoo et al., 1999). It is only the compound 
mutant embryos of Meox1-/-; Meox2-/- that display a dramatic phenotype associated with 
disrupted somite development. In these embryos, the axial skeleton fails to develop and 
most skeletal muscles are absent or reduced in size (Mankoo et al., 2003). Interestingly, in 
cell cultures, overexpression of Meox1 does not induce myogenesis and while a dominant 
negative Meox1 has been shown to downregulate Pax3 and Gli2 expression and inhibit 
myogenesis in the P19 stem cells (Petropoulos et al., 2004), Meox1 mutant mice exhibit mild 
defects in sclerotome-derived vertebral and rib bones (Mankoo et al., 2003) rather than 
showing any overt muscle defects. 
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3.3. Roles of histone acetyltransferases in myogenic expression 
Not only are extracellular signals crucial for the proper induction of MRFs, but intracellular 
prompts involving acetyletransferases play a fundamental role as well. CBP and p300 are 
required for growth arrest and apoptosis (Vo and Goodman, 2001), and along with PCAF 
are required for terminal differentiation of myoblasts and transactivation of muscle specific 
promoters such as myosin heavy chain (MHC) and muscle creatine kinase (MCK) (Eckner et 
al., 1996; Polesskaya et al., 2001; Puri et al., 1997a; Puri et al., 1997b; Yuan et al., 1996). 
Embryonic stem cells lacking p300 or its HAT activity are strongly impaired in their ability 
to activate Myf5 and MyoD (Roth et al., 2003). When properly expressed, Myf5 and MyoD, 
in cooperation with MEF2 transcription factors and with p300 and CBP, mediate the 
activation of the secondary MRFs, myogenin and Mrf4. p300 has been shown to bind 
directly to MyoD (Sartorelli et al., 1997; Yuan et al., 1996), and both p300 and PCAF play a 
critical role in the maximal MyoD dependant transactivation; p300 acetylates histones H3 
and H4 and recruits PCAF to the promoter whereas PCAF acetylates MyoD to enhance 
transcription initiation, increase its affinity for DNA binding, and facilitate heterodimer 
formation with E proteins (Dilworth et al., 2004; Puri et al., 1997a; Sartorelli et al., 1999). 
However, MyoD has also been found to be acetylated in proliferating myoblasts where it is 
inactive, therefore further mechanisms besides simply acetylation are required for MyoD 
activation (Polesskaya et al., 2000). 
4. Impact of extracellular cues on MRF expression 
Ligands of RAR and RXR play important roles in the activation of myogenesis and this 
activation is highly dependent on the identity of the ligand. RA is required for proper 
somite formation (Maden et al., 1996; Maden et al., 2000; Niederreither et al., 1999), induction 
of specification genes Meox1, Meox2, and Pax3, and counteracts inhibitory signals such as 
BMP4 (Kennedy et al., 2009). RA signaling intersects with that of BMP4, as BMP4 and RA 
function antagonistically and have the capacity to counteract each other's inhibition of entry 
into skeletal and cardiac muscle lineages (Kennedy et al., 2009). Low concentrations of RA 
can regulate the levels of Myf5 implying the existence of a RARE in the Myf5 regulatory 
region (Carnac et al., 1993). RA also enhances MyoD and myogenin expression (Carnac et al., 
1993), and RA receptors and MyoD have been found to upregulate each other’s 
transcriptional activity; their transcriptional co-activation requires a RA receptor-MyoD 
complex that binds to MyoD DNA binding sites in muscle cells (Froeschle et al., 1998). RA is 
capable of inhibiting proliferation of myoblasts through inducing cell cycle arrest proteins 
(Alric et al., 1998) and in vitamin A deficient embryos, myogenin is downregulated (Maden 
et al., 2000) providing a link between RA and myoblast maturation. 
RA and bexarotene are both capable of inducing skeletal myogenesis in the P19 stem cells, 
however, they do so through differential activation of crucial specification genes (Le May et 
al., 2011). Bexarotene primarily activates Meox1 while RA mainly activates Pax3. 
Nontheless, both ligands are equally capable of inducing later target genes such as MyoD 
and myogenin. Alternatively, only bexarotene is capable of inducing myogenesis in ES cells 
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to a significant level (Le May et al., 2011). Furthermore, treatment of these cells with 
bexarotene gives long, mature, multinucleated myofibers. 
4.1. Stem cell as a model for study of myogenic differentiation 
It is highly advantageous to use stem cell tissue cultures to study the importance of 
specification genes in a controlled environment to understand their relationship with each 
other and their regulation by extracellular signaling molecules. Specification factors exist in 
a very complex relationship and have the ability to autoregulate and cross-regulate one 
another (Petropoulos et al., 2004).  
In P19 stem cell cultures, Pax3 overexpression can induce Meox1 but is unable to activate 
Gli2 and a dominant negative Pax3 mutation does not affect Gli2 levels. Conversely, Gli2, 
which also has the ability to upregulate Meox1, can upregulate Pax3 while the dominant 
negative Gli2 P19 cells downregulate Meox1, Pax3, and MyoD expression and inhibits 
myogenesis. Lastly, Meox1 can activate the expression of Gli2 but overexpression of this 
protein is insufficient to induce Pax3 or skeletal myogenesis (Petropoulos et al., 2004). The 
ability of each of these factors to induce each other, or, in their absence, completely abolish 
myogenesis underlines the importance of these factors in the specification process.  
Wnt signaling via β-catenin is also essential and sufficient for the induction of specification 
factors Pax3, Meox1, and Gli2 and in P19 stem cells, a dominant negative β-catenin inhibits 
Pax3, Gli2, Meox1 and MyoD expression and abolishes myogenesis (Petropoulos et al., 2002). 
This is not surprising since mutations of either Gli2, Meox1, or Pax3 in these cells will 
abrogate myogenesis (Petropoulos et al., 2004). Pax3 expression is essential and sufficient for 
the expression of the transcription factor Six1 and the induction of skeletal myogenesis 
(Ridgeway et al., 2001). Its overexpression induces Myf-5, MyoD, and myogenin expression 
(Maroto et al., 1997) whereas a dominant negative Pax3 in P19 cells results in a loss of MyoD 
and myogenin expression and subsequent myogenesis (Ridgeway et al., 2001). 
4.2. Significance of a separate RXR signaling pathway  
The importance of a separate, rexinoid signaling pathway in skeletal muscle development 
non-overlapping with RA signal transduction is demonstrated by the fact that an RXR 
selective ligand, bexarotene effectively enhances skeletal myogenesis in mouse ES cells that 
respond poorly to RA (Le May et al., 2011). This difference in the two signaling pathways 
stems from differential activation of very early genes involved in crucial lineage 
specification, although both bexarotene and RA are dependent on functional β-catenin 
signaling (Le May et al., 2011). It is intriguing that a cell type such as ES cells, that has thus 
far been relatively resistant to RA-induced skeletal muscle differentiation develops so well 
in the presence of an RXR selective ligand, especially considering these cells do not posse 
the necessary machinery to synthesize 9-cis RA, the purported endogenous ligand (Chen 
and Khillan, 2010). It appears that P19 cells have the ability to differentiate by both retinoid 
and rexinoid signaling instigated pathways while ES cells respond well only to rexinoid 
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mediated pathways. Similarly, RAC65 cells resistant to RA-induced skeletal muscle and 
neuronal conversion (Costa and McBurney, 1996) demonstrate efficient skeletal 
differentiation when treated with RXR selective ligand (Le May et al., 2011). The ability of 
rexinoid to bypass the dominant negative RAR inhibition in RAC65 cells is not unique to 
skeletal muscle and has also been documented for neuronal differentiation as well (Yokota 
and Ohkubo, 1996). Finally, RXR is able to activate target genes involved in RA signaling 
that cannot be induced by RARs as is the case with the response element in the CRBPII 
(Cellular Retinol Binding Protein Type II) gene which contains a DR1, underscoring the 
possibility of RXR/RXR and RXR/RAR independent pathways (Mangelsdorf et al., 1991). 
It remains to be determined which specific co-activators are recruited by RXR in the 
enhancers or promoters of target genes during skeletal myogenesis. RXR homodimers or 
RXR permissive heterodimers might recruit a separate set of co-activators and therefore 
differentially control gene expression. It could be that the unique ability of bexarotene 
versus RA to control the transcription factor’s interactions with co-activators is the method 
by which distinct and even competing signaling pathways can be distinguished. 
4.3. Unsaturated fatty acids activate RXR  
The physiological significance of 9-cis RA signaling is debated due to a lack of consensus on 
its existence in the developing embryo. However, the enzymes that contribute to its 
biosynthesis are well documented (Mertz et al., 1997; Romert et al., 1998) in addition to its 
ability to induce the formation of homodimers that bind to DR1 sequences (Zhang et al., 
1992). The lack of a known ligand is hardly reason to exclude RXR as physiologically 
significant in vivo and a major factor that supports the presence of an active endogenous 
ligand is the fact that RXR tetramers cannot dissociate without agonist binding.  
Studies using RXR ligand-detector mice have identified specific regions of the spinal cord as 
major sites of endogenous rexinoid production and classify naturally occurring poly-
unsaturated fatty acids, including docosahexaenoic acid (DHA) as a major endogenous 
ligand for RXR in the mouse brain (Ahuja et al., 2003; de Urquiza et al., 2000). When 
characterized in the ligand binding domain of RXR-α, DHA has a significantly higher 
number of ligand-protein contacts than 9-cis and certain synthetic ligands and also has the 
ability to activate RXR homodimers as well as synergistically activate the RXR-RAR 
heterodimers in combination with all-trans RA (Lengqvist et al., 2004). It remains to be 
determined if this ligand is functional in all tissues or whether there are other yet 
undiscovered ligands. Presently, additional unsaturated fatty acids, including 
docosapentaenoic, arachidonic, and oleic acids, also have been found to bind and activate 
RXR, suggesting that this ability is not exclusive for DHA. Irrespective of whether an 
endogenous RXR ligand does indeed exist, the ability to control cell growth and 
differentiation through targeting RXR with highly selective ligands confers many therapeutic 
applications to this unique receptor. 
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5. Therapeutic potentials of rexinoids  
It is unknown whether RXR homodimer or RXR permissive heterodimer signaling is the 
main mechanism governing skeletal muscle differentiation. Regardless, controlling cell 
processes using RXR selective ligands underlines the fact that two distinct and possibly 
overlapping pathways exist. Moreover, RAR-independent rexinoid signaling provides 
another route of achieving cell cycle arrest and differentiation when RA signaling is 
aberrant, a situation frequently seen in cancer where differentiation often appears to result 
in loss of a malignant phenotype (Gokhale et al., 2000).  
RXR-α overexpression sensitizes tumors to rexinoid-induced anti-growth effects, cellular 
differentiation, decreased cell proliferation, apoptosis of some type of cancer cells, and 
prevention of angiogenesis and metastasis (Qu and Tang, 2010). Bexarotene, has been 
approved by the FDA for use in the treatment of refractory or persistent cutaneous T-cell 
lymphoma and has the ability to reduce tumor development in several other cancers (Duvic 
et al., 2001; Wu et al., 2002). However, the use of this compound in the treatment of lung and 
breast carcinomas has yielded disappointing results (Tanaka et al., 2009) demonstrating our 
lack of understanding of the molecular mechanisms underlying rexinoid-induced antitumor 
effects and RXR-induced multi-pathway activation.  
One of the reasons rexinoids seem such promising chemotherapeutic compounds compared 
to retinoids, is that retinoids have numerous side effects which severely limit the dosage and 
efficacy while rexinoids display mild toxicity. Furthermore, RXR expression is rarely lost in 
human tumors whereas RAR expression is frequently lost or reduced in various cancers 
(Sun and Lotan, 2002; Umesono et al., 1989). Since p53 abnormalities are reported in more 
than 50% of human cancers, and p21 is rarely mutated (Shiohara et al., 1994; Tanaka et al., 
2007), RXR mediated induction of p21 is a promising therapeutic target for these cancers. 
The study of myogenic differentiation may provide some answers to new target genes as the 
development and progression of cancer involves aberrations in the same mechanisms that 
regulate cell differentiation during embryogenesis. It remains to be revealed which other 
genes can also be targeted by rexinoids and which specific interactions take place that we 
can study and apply to our development of more potent and effective therapeutics. 
Pluripotent stem cells closely simulate embryonic development and present a model system 
with which to dissect signaling pathways of target receptors in controlled environments. 
They hold a tremendous potential for cell-based therapies through their capacity to grow 
and regenerate new tissues. Many diseases including muscular dystrophies, cancer, AIDS, 
and even normal conditions such as aging show prominent muscle loss that would benefit 
enormously from regenerative cell-based therapies. However, our ability to use stem cells in 
muscle-wasting disorders has been limited due to the low rate of myogenic differentiation in 
ES cell cultures and the difficulty in identifying and isolating progenitor cells. To harvest the 
full potential of these cells in therapies, it is imperative that we find small molecule inducers 
capable of efficiently directing stem cells into skeletal muscle lineage. Attempts at using RA 
in ES cell cultures have thus far yielded disappointing results; however, the ability of 
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rexinoids to induce these cells has not yet been fully explored. Understanding the myogenic 
pathway in vivo as well as deciphering differentiation cues to culture pure populations of 
myogenic progenitors will prove a vital tool in the treatment of such devastating diseases. 
6. Conclusion 
RXR selective ligand is an effective inducer of skeletal myogenesis not only in the P19 
pluripotent stem cells, but also in the mouse ES cells which have thus far been relatively 
resistant to RA induction. RXR specific signaling plays an important role in this process 
through a separate RAR-independent mediated pathway. It appears that RA and rexinoid 
enhance skeletal myogenesis through differential activation of early developmental genes. 
Our study demonstrates that activation of RXR causes an increase in the mesodermal Meox1 
gene while RA induces the skeletal specific gene Pax3. It will be interesting to uncover other 
novel genes targeted by rexinoid. Determining the molecular mechanism by which rexinoid 
exerts its effects to enhance skeletal myogenesis is challenging due in part to the complexity 
of the developmental systems in which it exerts its effects as well as the intricate relationship 
of protein complexes and gene regulation. Since ES cells closely recapitulate the properties 
of the developing embryo, elucidating these molecular pathways will be imperative in the 
manipulation of stem cell progenitors and aid in the generation of pure populations of 
skeletal myocytes to use in the treatment of muscle-related diseases.  
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